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A pentapeptide with analgesic activity has been isolated from human lung squamous cell carcinoma and 
from three other types of propagated tumors of human lung small-cell carcinoma (SCC), adenoma (AD) 
and large-cell carcinoma (LCC) in nude mice. The amino acid sequence of the peptide has been revealed 
to be H-Thr-Ser-Lys-Tyr-Arg-OH, which is exactly the same as that of neo-kyotorphin, an analgesic peptide 
originally isolated from bovine brain [(1982) Life Sci. 31, 17331. No neo-kyotorphin could be isolated from 
normal lung tissue using the same procedures as those used for carcinomas. The results suggest hat the 
presence of neo-kyotorphin in the lung carcinoma may represent he ectopic expression of peptide hormone. 
Our findings constitute the first example of a human lung carcinoma producing analgesic peptide. 
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1. INTRODUCTION 
Human lung small-cell carcinoma (SCC), 
squamous cell carcinoma (SQCC), adenoma (AD) 
and large-cell carcinoma (LCC) cover most types 
of the lung carcinoma identified in the clinic. 
Among them SCC amounts to nearly 20% of the 
identifiable human lung carcinoma [l]. These 
neoplasms are frequently a source for ectopic hor- 
mone production [l-7]. Most notable among the 
peptide hormones detected in extracts of lung car- 
cinoma and at elevated levels in the plasma of pa- 
tients with these tumors were ACTH [2,9], 
prolactin [2], oxytocin [2], calcitonin [9], 
bombesin [lo], physalamin [ 111, neurotensin [121, 
etc. It has been suggested and confirmed that many 
of the clinical symptoms manifested by patients 
with lung carcinoma can be attributed to increased 
peptide hormones [S-7]. 
* To whom correspondence should be addressed 
Searching for presently undiscovered peptide 
hormones that may cause some kinds of syndrome 
or serve as a potential peptide marker in the screen- 
ing of patients with lung carcinoma, we have in- 
vestigated most of the human lung carcinomas and 
found that an analgesic pentapeptide, neo- 
kyotorphin, is richly presented in four types of dif- 
ferent human lung carcinomas. Here we report the 
isolation, sequence determination, synthesis and 
analgesic activity of the peptide. 
2. MATERIALS AND METHODS 
2.1. Tumors 
Human lung SQCC was resected irectly during 
operation from a 40-year old man with apparent 
endocrinopathies. SCC from a 69-year old man, 
AD from a 72-year old man and LCC from a 
57-year old man were separately propagated in 
nude mice and resected after 45, 21 and 14 days, 
respectively. 
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2.2. Extraction and isolation 2.3.4. Carboxypeptidase Y digestion 
Four types of lung carcinoma obtained were 
separately homogenized and extracted in 5 vols 
(v/w) of 1 M acetic acid containing 1 mM EDTA, 
1 mM phenylmethylsulfonyl f uoride (PMSF) and 
1.5 PM pepstatin for 24 h at 4°C. After centrifuga- 
tion at 20000 x g for 20 min, the supernatants 
were lyophilized to give the crude extracts. 
The isolation details described below for human 
SQCC, the procedures and results of isolation and 
purification for the other three types of prop- 
agated carcinoma were very similar and not shown 
here. 
For the sequence determination of the COOH- 
terminal portion of the peptide, 10 nM of the sm- 
ple was dissolved in 200 pl of 0.1 M ammonium 
acetate (pH 5.7). Carboxypeptidase Y (1 /I&, from 
Boehringer Mannheim) was then added and the 
digestion was performed at 37°C. Aliquots of reac- 
tion mixture were taken out at the time intervals of 
0, 30 and 240 min. The lyophilized materials were 
then passed on the amino acid analyzer 
(LKB-4400). As a control, the peptide was in- 
cubated under the same conditions without adding 
the enzyme. 
The crude extract of SQCC was then deposited 
on a Sephadex G-50 (fig.1) column (2.3 x 90 cm) 
and eluted with 0.5 M acetic acid. Six fractions 
thus obtained were collected and freeze-dried. The 
fraction E that possessed a stimulating activity on 
a guinea pig ileum was rechromatographed on a 
Sephadex G-25 (superfine) column (2.3 x 90 cm) 
and eluted with the same solvent as used in the first 
gel-filtration. The active fraction D from second 
gel-filtration was subsequently purified by reverse- 
phase high performance liquid chromatography 
(RP-HPLC). The experimental conditions used for 
HPLC are given in the legend to fig.2. 
2.4, Synthesis 
Neo-kyotorphin was synthesized by the manual 
conventional liquid method. Protected serine, 
BOC-Ser(OBZ)-OH, was first coupled with H- 
Lys(Z)-OCH3 in the presence of DCCI to afford 
BOC-Ser(OBZ)-Lys(Z)-O~H3, which, after 
removal of the protecting group by TFA, was fur- 
ther reacted with BOC-Thr(OBZ)-OH by employ- 
ing the DCCI method and then saponified in the 
KOH solution to obtain a protected tripeptide, 
BO~~Thr(OBZ)-Ser(OBZ)-Lys(Z~-OH (I). 
2.3. Amino acid sequence determination 
2.3.1. Automatic Edman degradation 
2 nM of the sample (the peak denoted NK in 
fig.2B) was sequenced using a 470 A gas-phase se- 
quencer (Applied Biosystems Inc.) with an 
automatic PTH-amino acid converter. The 
phenylthiohydantoin amino acids (PTH-amino 
acids) were identified by an on-line RP-HPLC. 
BOC-Tyr(OBZ)-OH and H-Arg(NO2~-OCH~ 
was condensed by the DCCI method and then 
treated by TFA to form a protected dipeptide, H- 
Tyr(OBZ)-Arg(NOz)-OCH3 (II). 
I and II were condensed in the presence of t- 
butylchloroformate and ~-methylmorpholine to 
give BOC-Thr(OBZ)-Ser(OBZ)-Lys(Z)-Tyr(OBZ)- 
Arg(NO$-OCH3 (III). 
2.3.2. Fast atom bombardment mass spectrometry 
(FAB-MS) 
FAB-MS was carried out using a Varian MAT 
711 mass spectrometer equipped with a fast atom 
gun. The peptide (5 nM) in 2 ~1 glycerol was load- 
ed onto a probe tip. Spectra were recorded at 300 s 
per decade in mass. 
After converting III to corresponding acid by 
KOH, the final deprotection of the protected pen- 
tapeptide was successively carried out with 
catalytic hydrogenation (Hz-PdfC) and hydrolyzed 
by TFA to afford a crude product. The crude 
product thus obtained was purified by means of gel 
filtration on a Sephadex G-10 column to form a 
pure pentapeptide, neo-kyotorphin (IV). 
2.3.3. Manual sequence determination 2.5. Analgesic a&t~vity of Leo-kyot~r~~i~ 
Manual sequence determination of the peptide 
was performed by using a colored Edman degrada- 
tion method, where DABITC was used instead of 
PITC [15]. DABITC-amino acids obtained during 
the sequencing were identified in thin-layer sheets. 
The analgesic activity of synthetic neo- 
kyotorphin was determined by the tail-pinch 
method on eighteen assayed mice. Pain responses 
were recorded during IO-40 min after administra- 
tion of the sample. 
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3. RESULTS 
3.1. Purification procedures 
Fig.lA shows the initial fractionation of the 
crude human SQCC extract. Second gel filtration 
of active fraction E from fig. 1A on Sephadex G-25 
is presented in fig.lB. The active fraction D from 
fig.lB was then repurified twice by RP-HPLC 
(shown in fig.2) and provided a pure peptide 
(denoted NK), on which amino acid analysis and 
sequencing were performed. 
3.2. Amino acid analysis 
In table 1, the results of amino acid composition 
of the purified peptide are depicted. It can be seen 
that the peptide has a very good amino acid in- 
tegral and the length of the peptide is presumed to 
be five amino acids. 
3.3. Sequencing 
Sequence determination of the purified peptide 
on a nanomole scale proceeded successfully to the 
carboxyl end in both automatic and manual Ed- 
man degradation procedures. The results obtained 
(fig.3) suggest that the peptide has the amino acid 
sequence of H-Thr-Ser-Lys-Tyr-Arg-OH. Diges- 
tion of the peptide by carboxypeptidase Y released 
Arg (8.4 nM) and Tyr (2.9 nM). The COOH- 
terminal sequence thus revealed is in good agree- 
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Fig. 1. Gel-permeation chromatography of crude extract 
of human AD on the Sephadex G-50 column (A) and 
second gel-permeation chromatography of fraction D 
from (A) on the Sephadex G-25 column (B). Flow rate: 
20 ml/h, column size and elution solvents are given in 
the text. 
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Fig.2. Reverse-phase HPLC purification of neo- 
kyotorphin. (A) The initial purification of fraction E 
from fig.lB on an analytical pBondapak Cl* column 
(Waters 39 300 mm). The peak denoted NK was 
collected for further purification. (B) Repurification of 
NK by second RP-HPLC. The peak denoted NK in (B) 
provided a pure neo-kyotorphin. The RP-HPLC 
apparatus consisted of two Waters 6000 A pumps, a 
model 460 solvent programmer, a model 450 variable 
wavelength detector and a model 730 data module. 
Elutions were made using a linear gradient of O-60% of 
acetonitrile (containing 0.01 M HFBA, v/v) at a flow 
rate of 0.6 ml/min. 
ment with that determined by the Edman 
degradation. 
The results of sequence determination of the 
peptide by FAB-MS are shown in fig.4. The types 
of peptide fragmentation by FAB are deduced ac- 
cording to Schufer [16]. As can be seen, M + H 654 
confirmed the amino acid composition and the 
COOH-terminal amino acid. Ions m/e 74, 189,317 
and 480 indicate the presence of amino- 
carboxonium ions (ACO), while ions m/e 553, 
466, 338 and 175 show the cleavage of amino- 
carboxy ions (AC) with charge on the -COOH 
Table 1 
Amino acid composition of neo-kyotorphin 
Amino acid Residues per 
molecule 
Nearest integer 
Thr 1.06 1 
Ser 0.99 1 
Tyr 0.94 1 
LYS 1.01 1 
Arg 0.99 1 
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NH2 - Thr - Ser - Lys - Tyr - Arg - OH 
_--A- 
___ __. __s. __a __a 
___ -__ 
Fig.3. Determined sequence of neo-kyotorphin: ( -) 
determined by automatic Edman degradation; ( -- - ) 
determined by manual Edman degradation; ( --- ) C- 
terminal sequence deduced by carboxypeptidase Y 
digestion. 
MG653 MtH 654 
Fig.4. Data from fast atom bombardment mass 
spectrometry of neo-kyotorphin. (a-d) Different forms 
of cleavages of neo-kyotorphin: (a) cleavage of the 
amino-alkyl bond to form an amino-amide ion (A.A); 
(b) cleavage of the same bond to form an alkyl-carboxyl 
ion (ALKC); (c) cleavage of the amide bond to form an 
amino-carboxyl ion (AC); (d) cleavage of the amide 
bond to form an amino-carboxonium ion (ACO). The 
data of peak m/e show the peaks formed in the 
chromatogram, while the data listed in parentheses show 
the peaks not formed in the chromatogram. 
moiety. Ion m/e 553 suggests Thr at the 
NHz-terminus of the peptide (m/e 553 =654 
(M + H)- 101 (Thr)). Accepting Thr to be the 
NHz-terminal amino acid, one can easily add Ser 
(553-466), Lys (466-338), Tyr (338-175) and Arg 
successively. 
Based on these data, it is unambiguously con- 
cluded that the amino acid sequence of the peptide 
is H-Thr-Ser-Lys-Tyr-Arg-OH. 
3.4. Synthesis of neo-kyotorphin 
Fig.5 shows the scheme of synthesis for neo- 
kyotorphin. The total yield of the final purified 
peptide was 15% (w/w). Both the amino acid com- 
position and behaviour on RP-HPLC of the syn- 
thetic sample were identical to the authentic 
peptide (not shown). 
Ecc-Thr(oBz)ar(oNZbw(z)-oN 
(I) I 1 (II) 
ClCoo-eUt/NNB 
v 
~-~hr(o~)-s.r(o~Bz)_Lys(z)-Tyr(oaz)-A~(Noz)-~3 
1. KON 
2. HZ-i+ 
(III) 
3. TFA 
Fig.5. The synthetic scheme of neo-kyotorphin by the 
conventional liquid method. t-BOC, tert-butyloxy- 
carbonyl; Bz, benzyl; Z, benzylcarbonyl; NOz, nitro; 
DCCI, N,N ‘-dicyclohexylcarbodiimide; NMM, 
N-methylmorpholine; TFA, trifluoroacetic acid; 
ClCOOBut, t-butylchloroformate. 
Actton time (m(n) 
Fig.6. Analgesic activity of synthetic neo-kyotorphin on 
mice. (-- -) The pain response on tested mice after 
intraventricular injection of the sample (5O~g). (-) 
The pain response of control group of mice. *** 
indicates that the p-value of the results obtained was 
<O.Ol. 
3.5. Analgesic activity of neo-kyotorphin 
Synthetic neo-kyotorphin showed a dose- 
dependent effect on mice after intraventricular in- 
jection. A dose of 100 pug (152 nM) of synthetic 
neo-kyotorphin caused strongly spasmodic action 
on the tested mice, while 50 pg (76 nM) of the sam- 
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ple exhibited profound analgesic activity (fig.6). 
The analgesic activity initiated from 10 min after 
administration and could last for about 30 min. 
4. DISCUSSION 
The present results draw an interesting conclu- 
sion that high levels of neo-kyotorphin are present 
in four kinds of human carcinoma. Neo- 
kyotorphin has been proved to be an analgesic pep- 
tide by Takagi et al. [17] and by this work. Our 
findings also constitute the first example of a 
human lung carcinoma producing analgesic 
peptide. 
It is still unknown whether the tumor-derived 
hormone production is a simple reflection of 
derepression of genetic material consequent to 
dedifferentiation or whether the hormones exert a 
positive influence on the tumor growth of the 
tumor cell [18]. However, the finding of peptide 
hormones which specifically occur in the tumor 
cell, but not in the normal cell, suggests that the 
probability for success in using the plasma concen- 
tration of the peptide as a biochemical marker for 
this disorder is high. 
The results of a computer search for possible se- 
quence homology of neo-kyotorphin indicated that 
the amino acid sequence of neo-kyotorphin is iden- 
tical to that of the five C-terminal amino acid 
residues of hemoglobin A-chain (Thr-137 to 
Arg-141). As the amino acid residue preceding 
Thr-137 is Leu, it seems likely that neo-kyotorphin 
is an enzymatically cleaved fragment of 
hemoglobin A-chain, by an endogenous 
chymotrypsin-like enzyme. This possibility needs 
to be proved by some further work. 
It is still too early to evaluate the physiological 
importance of neo-kyotorphin. We hope that the 
further work including the studies on the com- 
prehensive biological activity, the regional 
distribution, the structure-activity as well as the 
establishment of antiserum against neo-kyotorphin 
and the radioimmunoassay system will throw some 
new light on the peptide. 
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